Ivana Gojo

Ivana Gojo

Auto-generated profile, based on publicly available information

Ivana Gojo

University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2006 in Blood
Verified
Journal Article
Open access
PDF file
IGIvana Gojo
Ivana Gojo
AJAnchalee Jiemjit
Anchalee Jiemjit
JTJane B. Trepel
Jane B. Trepel
ASAlex Sparreboom
Alex Sparreboom
WFWilliam D. Figg
William D. Figg
JKJudith E. Karp
Judith E. Karp
MS-275 is a benzamide derivative with potent histone deacetylase (HDAC) inhibitory and antitumor activity in preclinical models. We conducted a phase 1 trial of orally administered MS-275 in 38 adults with advanced acute leukemias. Cohorts of patients were treated with MS-275 initially once weekly × 2, repeated every 4 weeks from 4 to 8 mg/m2, and after 13 patients were treated, once weekly × 4, repeated every 6 weeks from 8 to 10 mg/m2. The maximum-tolerated dose was 8 mg/m2 weekly for 4 weeks every 6 weeks. Dose-limiting toxicities (DLTs) included infections and neurologic toxicity manifesting as unsteady gait and somnolence. Other frequent non-DLTs were fatigue, anorexia, nausea, vomiting, hypoalbuminemia, and hypocalcemia. Treatment with MS-275 induced increase in protein and histone H3/H4 acetylation, p21 expression, and caspase-3 activation in bone marrow mononuclear cells. No responses by classical criteria were seen. Our results show that MS-275 effectively inhibits HDAC in vivo in patients with advanced myeloid leukemias and should be further tested, preferably in patients with less-advanced disease.

1 January 2007 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
BABorislav Alexandrov Alexiev
Borislav Alexandrov Alexiev
WWWenle Wang
Wenle Wang
YNYi Ning
Yi Ning
SCSaranya Chumsri
Saranya Chumsri
IGIvana Gojo
Ivana Gojo
XZXianfeng F Zhao
Xianfeng F Zhao
Myeloid sarcoma (MS) is a neoplasm of immature granulocytes, monocytes, or both involving any extramedullary site. The correct diagnosis of MS is important for adequate therapy, which is often delayed because of a high misdiagnosis rate. To evaluate the lineage differentiation of neoplastic cells in MS by immunohistochemistry, and to correlate the results with clinicopathologic findings and cytogenetic studies. Histologic and immunohistochemical examinations were performed on formalin-fixed paraffin-embedded tissue samples from 13 cases of MS. They were classified according to the World Health Organization criteria. Chromosomal analysis data were available in 11 cases. Clinical, pathological, and cytogenetic findings were analyzed. The study included six male and seven female patients with an age range of 25 to 72 years (mean, 49.3 years) and a male to female ratio of 1:1.2. MS de novo occurred in 4/13 (31%) of cases examined. The most sensitive immunohistochemical markers were CD43 and lysozyme present in all cases with MS (13/13, 100%). All de novo MS showed a normal karyotype, monoblastic differentiation, and lack of CD34. The most common chromosomal abnormalities in MS associated with a hematopoietic disorder were trisomy 8 and inv(16) (2/11, 18%). An immunohistochemical panel including CD43, lysozyme, myeloperoxidase (MPO), CD68 (or CD163), CD117, CD3 and CD20 can successfully identify the vast majority of MS variants in formalin-fixed paraffin-embedded tissue sections. The present report expands the spectrum of our knowledge showing that de novo MS has frequent monoblastic differentiation and frequently carries a normal karyotype.


1 September 2007 in Leukemia Research
Verified
Journal Article
Closed access
IGIvana Gojo
Ivana Gojo
MTMichael L. Tidwell
Michael L. Tidwell
JGJacqueline Greer
Jacqueline Greer
NTNaoko Takebe
Naoko Takebe
KSKaren Seiter
Karen Seiter
JKJudith E. Karp
Judith E. Karp

10 May 2004 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
IGI Gojo
I Gojo
CGC Guo
C Guo
CSC Sarkodee-Adoo
C Sarkodee-Adoo
BMB Meisenberg
B Meisenberg
AFA Fassas
A Fassas
GTG Tricot
G Tricot

24 October 2005 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
IGI Gojo
I Gojo
BMB Meisenberg
B Meisenberg
CGC Guo
C Guo
AFA Fassas
A Fassas
AMA Murthy
A Murthy
ARA P Rapoport
A P Rapoport